American

American Chemical Society Honors Syngenta’s Camilla Corsi With 2026 International Award for Agrochemical Research

American Chemical Society Names Syngenta’s Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals Camilla Corsi, Head of Crop Protection Research & Development at Syngenta, is the winner of the prestigious 2026 American Chemical Society (ACS)…

Read MoreAmerican Chemical Society Honors Syngenta’s Camilla Corsi With 2026 International Award for Agrochemical Research
European

European Commission Expands Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status Gilead Sciences, Inc. announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult…

Read MoreEuropean Commission Expands Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
BASF

BASF and NEO Corporate Partner to Accelerate Innovation in Personal Care Solutions

BASF and NEO Corporate Launch Strategic Partnership to Advance Innovation in Personal Care Solutions BASF and NEO Corporate Public Company Limited announced a strategic partnership to advance next generation Personal Care solutions through the joint development of innovative formulations, ingredient technologies and…

Read MoreBASF and NEO Corporate Partner to Accelerate Innovation in Personal Care Solutions
NTx Bio

NTx Bio Enables Personalized Cancer Vaccine Manufacturing for Baylor College of Medicine’s Phase 1 Melanoma Trial

NTx Bio Powers Baylor College of Medicine’s Manufacturing of a Personalized Cancer Vaccine in Diakonos Oncology’s Phase 1 Refractory Melanoma Trial NTx Bio, a leader in next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College…

Read MoreNTx Bio Enables Personalized Cancer Vaccine Manufacturing for Baylor College of Medicine’s Phase 1 Melanoma Trial
UNC Health

UNC Health Launches UNC Health Ventures to Expand Strategic Investment Platform

UNC Health Launches UNC Health Ventures, Marking Next Phase of Strategic Investment Platform UNC Health today announced the rebranding of Rex Health Ventures and the launch of UNC Health Ventures, its corporate venture capital and strategic investment platform. The platform builds…

Read MoreUNC Health Launches UNC Health Ventures to Expand Strategic Investment Platform
Cardio

Cardio Diagnostics Launches In-House Testing at New CLIA-Certified Iowa Laboratory

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City Cardio Diagnostics Holdings, Inc. an AI-driven precision cardiovascular medicine company, announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa.…

Read MoreCardio Diagnostics Launches In-House Testing at New CLIA-Certified Iowa Laboratory
TAGRISSO

TAGRISSO Plus Savolitinib Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a…

Read MoreTAGRISSO Plus Savolitinib Improves Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer
Enhertu

Enhertu Shows Significant Progression-Free Survival Benefit in HER2-Mutant Advanced NSCLC

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant…

Read MoreEnhertu Shows Significant Progression-Free Survival Benefit in HER2-Mutant Advanced NSCLC
Protolabs

Protolabs Supports MIT Research to Advance U.S. Medical and Aerospace Manufacturing Innovation

Protolabs Supports MIT Industrial Performance Center Research Fellows to Accelerate U.S. Medical and Aerospace Manufacturing Innovation Protolabs the world’s leading provider of digital manufacturing services, today announced a grant to support research fellows at the MIT Industrial Performance Center as…

Read MoreProtolabs Supports MIT Research to Advance U.S. Medical and Aerospace Manufacturing Innovation
Artera Enrolls

Artera Enrolls First Patient in DIRECT-AI Registry for AI-Powered Prostate Cancer Care

Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests,announced the enrollment of the first patient in its DIRECT-AI registry…

Read MoreArtera Enrolls First Patient in DIRECT-AI Registry for AI-Powered Prostate Cancer Care